Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Gilead cancer...

    Gilead cancer immunotherapy wins US approval with 373,000 dollars price

    Written by Ruby Khatun Khatun Published On 2017-10-21T10:59:25+05:30  |  Updated On 21 Oct 2017 10:59 AM IST
    Gilead cancer immunotherapy wins US approval with 373,000 dollars price

    A new therapy for a type of lymphoma developed by Kite Pharma, which was acquired by Gilead Sciences Inc, won U.S. approval on Wednesday, marking the second approval for this potentially revolutionary approach to fighting cancer.


    Gilead said the price for the therapy with the one-time administration would be $373,000.


    Gilead Sciences shares rose almost 4 percent to $83 in extended trading.


    The therapy, to be sold under the brand name Yescarta, is the second in a new class of cancer treatments known as chimeric antigen receptor T-cell therapy, or CAR-T, which reprograms the body's own immune cells to recognize and attack malignant cells.


    The first drug in the class, Novartis AG's Kymriah, costs about $475,000 for the one-time treatment. It was approved in August for B-cell acute lymphoblastic leukemia, the most common form of childhood cancer in the United States.


    Yescarta is approved to treat adults with relapsed or refractory large B-cell lymphoma, a type of non-Hodgkin lymphoma.


    "The approval of Yescarta brings this innovative class of CAR-T cell therapies to an additional group of cancer patients with few other options," Peter Marks, the Food and Drug Administration's director of biologics evaluation, said in a statement.


    Potentially curative CAR-T therapies are poised to revolutionize blood cancer treatment, offering therapies tailored to the individual patient.


    The treatments are made from a patient's own infection-fighting cells. They are extracted, genetically engineered to recognize cancer cells, and infused back into the patient, where they form an army to attack and destroy malignant cells, potentially for years.


    "Gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer," FDA Commissioner Scott Gottlieb said in a statement.


    In a pivotal clinical trial of more than 100 adults, 51 percent of patients treated with Yescarta achieved complete remission, far higher than what is typical with current standard-of-care treatments.


    "We conducted extensive research with commercial and government payers, as well as targeted cancer centers, to set a price that reflects the value represented by this innovation, and that supports accessibility of this personalized therapy," Gilead spokeswoman Amy Flood said in an emailed statement.


    Gilead agreed in August to pay $180 a share, or about $12 billion, for Kite two days before Kymriah won U.S. approval, boosting confidence in the entire CAR-T class.


    Similar CAR-T treatments are being developed by Juno Therapeutics Inc, bluebird bio Inc and others.


    (Reporting by Toni Clarke and Bill Berkrot; Additional reporting by Deena Beasley in Los Angeles; editing by Leslie Adler and Diane Craft)

    Amy FloodapprovalcancerCAR-TClinical TrialGileadGilead Sciencesimmune cellsimmunotherapyKite PharmaKymriahlymphomaNovartispharma newsScott GottliebT cell therapyUSYescarta
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok